Quintiles taps Google partner Tute Genomics for R&D

Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.

Trial tech outfit Clinical Ink merges with app upstart

Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.

PPD cozies up to trial site group with an eye on enrollment

PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.

Catalent shakes up its business with an eye on product launches

Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.

Evotec pairs up with Second Genome to gut out some R&D

Hybrid researcher Evotec has signed a deal with microbiomics biotech Second Genome to lend out its drug discovery capabilities in hopes of crafting treatments that harness the power of the gut.

WuXi dives into the CAR-T fray with new plant plans

WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies.

ACRO's advisory council chimes in on Big Pharma's R&D supergroup

The Association of Clinical Research Organizations (ACRO) assembled a group of CRO leaders to advise TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.

Altasciences partners up for early-stage R&D

Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.

Contractor Almac gets into the clinic with a candidate of its own

Contract drug developer Almac has reached a milestone in its efforts to develop in-house therapeutics, taking its top prospect into Phase I trials.

Icon doubles down on med tech with latest offering

Global CRO Icon is launching a new service catered to the specific needs of medical device and diagnostic developers, touting one of its recent acquisitions as key to the move.

Patheon snags another CMO amid its global expansion

Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.

WuXi eyes major growth in 2015 with plans to spend big

WuXi PharmaTech posted a record revenue year in 2014, and China's largest CRO is planning to increase its internal investments in hopes of delivering double-digit growth.

Enteris gets into contract manufacturing with new plant

Enteris BioPharma is looking to make some money on the side of its drug-delivery operation, opening a contract manufacturing facility and scouting for clients.

Catalent beefs up its European network for clinical supplies

Catalent is investing in infrastructure again, spending to flesh out its European network of storage and packaging facilities in response to an increase in demand on the continent.

Charles River embraces discovery in management shake-up

Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.

INC Research soars in its first post-IPO quarter

Months removed from a $150 million IPO, INC Research is looking to raise its profile among the world's largest CROs, inching toward the $1 billion annual revenue mark in the new year.

Icon rides a revenue leap into another growth year

CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015.

Quintiles shedding 270 jobs in a cost-cutting move

Global CRO Quintiles is planning to lay off about 270 workers, 1% of its payroll, in an effort to reduce "excess capacity," the company said.

WuXi borrows $165M to bankroll more M&A

Acquisitive Chinese CRO WuXi PharmaTech is borrowing up to $165 million to keep up its string of deals, eyeing investments in R&D and manufacturing.

Parexel stretches out its site network to speed up enrollment

CRO giant Parexel International has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.